Jason T Connor
Overview
Explore the profile of Jason T Connor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yarchoan M, Gane E, Marron T, Perales-Linares R, Yan J, Cooch N, et al.
Nat Med
. 2024 Apr;
30(4):1044-1053.
PMID: 38584166
Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may enhance responses to PD-1 inhibitors through...
2.
Fleming T, Wittes J, Fiuzat M, Bristow M, Rockhold F, Connor J, et al.
JACC Heart Fail
. 2024 Mar;
12(8):1317-1327.
PMID: 38530701
Clinical trials are vital for assessing therapeutic interventions. The associated data monitoring committees (DMCs) safeguard patient interests and enhance trial integrity, thus promoting timely, reliable evaluations of those interventions. We...
3.
Stevens G, Dolley S, Mogg R, Connor J
Contemp Clin Trials Commun
. 2023 Jun;
34:101100.
PMID: 37388218
A number of principal investigators may have limited access to biostatisticians, a lack of biostatistical training, or no requirement to complete a timely statistical analysis plan (SAP). SAPs completed early...
4.
Crippa A, De Laere B, Discacciati A, Larsson B, Connor J, Gabriel E, et al.
Trials
. 2020 Jun;
21(1):579.
PMID: 32586393
Background: Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Several prognostic molecular...
5.
Eklund M, Broglio K, Yau C, Connor J, Stover Fiscalini A, Esserman L
JNCI Cancer Spectr
. 2020 May;
4(2):pkaa016.
PMID: 32373780
No abstract available.
6.
Chamberlain J, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al.
Lancet
. 2020 Mar;
395(10231):1217-1224.
PMID: 32203691
Background: Benzodiazepine-refractory, or established, status epilepticus is thought to be of similar pathophysiology in children and adults, but differences in underlying aetiology and pharmacodynamics might differentially affect response to therapy....
7.
Butler C, van der Velden A, Bongard E, Saville B, Holmes J, Coenen S, et al.
Lancet
. 2019 Dec;
395(10217):42-52.
PMID: 31839279
Background: Antivirals are infrequently prescribed in European primary care for influenza-like illness, mostly because of perceived ineffectiveness in real world primary care and because individuals who will especially benefit have...
8.
Kapur J, Elm J, Chamberlain J, Barsan W, Cloyd J, Lowenstein D, et al.
N Engl J Med
. 2019 Nov;
381(22):2103-2113.
PMID: 31774955
Background: The choice of drugs for patients with status epilepticus that is refractory to treatment with benzodiazepines has not been thoroughly studied. Methods: In a randomized, blinded, adaptive trial, we...
9.
Eklund M, Broglio K, Yau C, Connor J, Stover Fiscalini A, Esserman L
JNCI Cancer Spectr
. 2019 Jul;
2(4):pky067.
PMID: 31360882
Background: WISDOM (Women Informed to Screen Depending on Measures of Risk) is a randomized trial to assess whether personalized breast cancer screening-where women are screened biannually, annually, biennially, or not...
10.
Butler C, Connor J, Lewis R, Broglio K, Saville B, Cook J, et al.
Br J Gen Pract
. 2018 Jun;
68(671):294-295.
PMID: 29853596
No abstract available.